MIMETAS, a global provider in human disease modeling, has expanded its ongoing partnership with Astellas to include automation and application support.
 
The Mimetas and Astellas partnership began in 2016 by accepting three scientists from Astellas for hands-on training at MIMETAS. In March 2023, the companies entered a strategic partnership to devise novel immuno-oncology therapies based on MIMETAS’ comprehensive tumor models. This partnership expands Astellas’ adoption of the MIMETAS platform leveraging automation and application support.
 
“We are truly honored by the trust of the Astellas team in our capabilities,” said Paul Vulto, CEO of MIMETAS. “Astellas is a true innovation leader that understands the importance of human-relevant tissue and disease modeling for novel therapy development. We will continue supporting Astellas with our expertise and technology to accelerate therapy development for today’s unmet medical need and contribute to Astellas’ vision to turn innovative science into patient benefits.”